

Serum Vitamin D and Risk of Bladder Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Alison M. Mondul¹, Stephanie J. Weinstein¹, Ronald L. Horst³, Mark Purdue², and Demetrius Albanes¹

Abstract

Background: The one previous prospective study of vitamin D status and risk of urinary bladder cancer found that male smokers with low serum 25-hydroxy-vitamin D [25(OH)D] were at a nearly two-fold increased risk. We conducted an analysis of serum 25(OH)D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Study and examined whether serum vitamin D binding protein (DBP) concentration confounded or modified the association.

Methods: Three hundred and seventy-five cases of bladder cancer were matched 1:1 with controls based on age (± 5 years), race, sex, and date of blood collection (± 30 days). Conditional logistic regression was used to estimate ORs and 95% confidence intervals (CI) of bladder cancer by prediagnosis levels of 25(OH)D.

Results: We found no strong or statistically significant association between serum 25(OH)D and bladder cancer risk (Q1 vs. Q4: OR, 0.84; 95% CI, 0.52–1.36; $P_{\text{trend}} = 0.56$). Further adjustment for, or stratification by, serum DBP did not alter the findings, nor was there a main effect association between DBP and risk.

Conclusion: In contrast to an earlier report, we observed no association between vitamin D status and risk of bladder cancer; this difference could be due to the inclusion of women and nonsmokers in the current study population or due to the differences in the distribution of vitamin D concentrations between the two study populations.

Impact: These findings may contribute to future meta-analyses and help elucidate whether the vitamin D–bladder cancer association varies across populations. *Cancer Epidemiol Biomarkers Prev*; 21(7); 1222–5. ©2012 AACR.

Introduction

Laboratory studies provide evidence that vitamin D promotes cell differentiation and decreases cell proliferation, invasion, angiogenesis, and metastasis (1, 2). Thus, it has been hypothesized that vitamin D may protect against cancer at multiple sites. Most epidemiologic evidence supports a protective association with colorectal cancer, but evidence concerning other cancers is inconsistent (1, 3). For urinary bladder cancer, only one study has examined vitamin D status, as measured by serum 25-hydroxyvitamin D [25(OH)D] concentration, which showed that male smokers with low 25(OH)D had a nearly 2-fold increased risk of bladder cancer compared with men with higher levels (4). Furthermore, few studies have examined the role of vitamin D binding protein

(DBP), the major carrier of 25(OH)D in circulation, in the association between vitamin D and risk of cancer. We undertook an analysis of serum 25(OH)D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Study and examined whether serum DBP concentration confounded or modified the vitamin D association.

Materials and Methods

The PLCO Study has been described in detail previously (5). Bladder cancer cases ($n = 369$) with prediagnosis serum available occurred during 13 years of follow-up. Controls were sampled with replacement from PLCO Study participants who were alive and cancer-free at the time the case was diagnosed and were matched 1:1 to cases on age (± 5 years), race, sex, and date of blood collection (± 30 days).

Details of the laboratory methods for measurement of 25(OH)D have been reported (6). DBP was measured in the laboratory of Dr. William Kopp (SAIC-NCI, Frederick, MD) by ELISA (R&D kits). Each batch contained 4 or 6 blinded quality control (QC) duplicates from 4 PLCO Study participants. The range of inter- and intrabatch coefficients of variation (CV) across the 4 sets of duplicates were: 25(OH)D, 3.7%–6.9% and 4.8%–8.1%, respectively; DBP, 3.2%–11.1% and 9.5%–12.6%, respectively.

Authors' Affiliations: ¹Nutritional Epidemiology Branch, ²Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland; and ³Heartland Assays, Inc., Ames, Iowa

Corresponding Author: Alison M. Mondul, National Cancer Institute, NIH, 6120 Executive Blvd, Ste. 320, Rockville MD 21045. Phone: 301-496-5626; Fax: 301-496-6829; E-mail: mondulam@mail.nih.gov

doi: 10.1158/1055-9965.EPI-12-0439

©2012 American Association for Cancer Research.

Conditional logistic regression was used to estimate ORs and 95% confidence intervals (CI) for bladder cancer by prediagnosis concentrations of 25(OH)D categorized as previously described (6). We also examined quartiles of DBP as well as the molar ratio of 25(OH)D:DBP [an estimate of free circulating 25(OH)D] and risk of bladder cancer.

Models were conditioned on the matching factors. Multivariable models were further adjusted for smoking status (never, current, former), pack-years of smoking (continuous), dairy consumption (continuous), and use of aspirin or ibuprofen (yes/no).

Subgroup analyses were conducted stratifying by age (<64, ≥64 years), sex (male, female), race (white, non-white), smoking (never or former, current), season

(sunnier: June–October, darker: November–May), study center (low UVB exposure latitude, moderate or high UVB exposure latitude; ref. 7), and DBP (<median, ≥median). Interaction was assessed using the likelihood ratio test.

Results

Characteristics of cases and controls are shown in Table 1. We did not observe a strong association between serum 25(OH)D and bladder cancer (Table 2). An inverted U-shaped association was suggested, particularly when 25(OH)D was categorized as season-specific quartiles. This was attenuated with multivariable adjustment and was not statistically significant. Adjustment for serum DBP did not alter the findings,

Table 1. Selected baseline characteristics [medians (interquartile range) or *n* (%)] for case and control subjects, PLCO Study

Characteristics	Controls (N = 364)	Cases (N = 369)	P
Age, y	64 (61–67)	64 (60–68)	Matched
Male	294 (80.8)	298 (80.8)	Matched
European descent	344 (94.5)	348 (94.3)	Matched
Height, cm	178 (170–183)	175 (168–180)	0.19
Weight, kg	84.7 (77.2–94.3)	83.2 (74.1–93.2)	0.12
Body mass index, kg/m ²	27.2 (24.7–30.1)	27.2 (24.4–29.5)	0.67
Education			
<High school	27 (7.4)	30 (8.1)	0.13
High-school graduate	71 (19.5)	83 (22.5)	
Some college or vocational training	108 (29.7)	131 (35.5)	
College graduate	66 (18.1)	54 (14.6)	
Postgraduate	91 (25.0)	71 (19.2)	
Smoking status			
Never	160 (44.0)	95 (25.6)	<0.0001
Former	169 (46.4)	217 (58.8)	
Current	35 (9.6)	57 (15.5)	
Hours spent in vigorous activity			
None	40 (11.0)	55 (14.9)	0.16
≤3 h/wk	204 (56.0)	193 (52.3)	
≥4 h/wk	96 (26.4)	89 (24.1)	
Family history of bladder cancer	6 (1.7)	7 (1.9)	0.71
Personal history of type 2 diabetes	30 (8.2)	33 (8.9)	0.73
Regular aspirin use	180 (49.5)	207 (56.1)	0.08
Regular ibuprofen use	85 (22.4)	108 (29.3)	0.07
Dietary and supplement intake (/d)			
Total energy, kcal	2,162 (1,628–2,656)	2,091 (1,520–2,665)	0.32
Vitamin D, μg	4.9 (3.4–7.6)	4.8 (3.2–7.1)	0.32
Calcium, mg	905 (682–1,266)	894 (606–1,188)	0.14
Dairy food (MyPyramid cup equivalents)	1.7 (1.1–2.5)	1.5 (0.9–2.3)	0.01
Red meat, g	68.5 (41.4–115.0)	78.2 (43.3–121.9)	0.26
Supplemental vitamin D, μg	0 (0–10.0)	0 (0–10.0)	0.87
Supplemental calcium, mg	0 (0–162)	0 (0–162)	0.96
Supplemental vitamin E, mg	13.5 (0–180)	13.5 (0–104)	0.67
Serum 25(OH)D, nmol/L	53.6 (39.5–68.1)	52.4 (39.6–65.8)	0.59
Serum DBP, μg/mL	237 (186–295)	232 (189–290)	0.68

Table 2. ORs and 95% CIs of baseline serum 25(OH)D and bladder cancer risk, PLCO

	No. of cases	No. of controls	OR (95% CI) ^a	OR (95% CI) ^b	OR (95% CI) ^c
25(OH)D, nmol/L					
<25	16	17	0.86 (0.38–1.94)	0.73 (0.29–1.84)	0.74 (0.29–1.87)
25–<37.5	54	63	0.75 (0.47–1.20)	0.71 (0.42–1.19)	0.72 (0.43–1.23)
37.5–<50	92	76	1.10 (0.75–1.63)	1.17 (0.76–1.80)	1.17 (0.76–1.80)
50–<75	158	144	1.0 (ref)	1.0 (ref)	1.0 (ref)
≥75	49	64	0.71 (0.46–1.09)	0.85 (0.53–1.35)	0.85 (0.53–1.38)
<i>P</i> _{trend} ^d			0.50	0.97	0.99
Season-specific quartiles ^e of 25(OH)D					
1	84	100	1.00 (0.65–1.52)	0.84 (0.52–1.36)	0.84 (0.51–1.38)
2	101	81	1.43 (0.96–2.13)	1.24 (0.80–1.92)	1.24 (0.79–1.93)
3	103	82	1.49 (1.00–2.21)	1.29 (0.84–1.99)	1.28 (0.83–1.98)
4	81	101	1.0 (ref)	1.0 (ref)	1.0 (ref)
<i>P</i> _{trend} ^f			0.95	0.56	0.58
Residual-adjusted quartiles ^g of 25(OH)D					
1	93	90	1.19 (0.78–1.83)	1.01 (0.53–1.64)	1.04 (0.63–1.71)
2	91	92	1.15 (0.77–1.70)	1.11 (0.72–1.71)	1.12 (0.72–1.74)
3	100	83	1.39 (0.91–2.12)	1.13 (0.71–1.81)	1.13 (0.70–1.82)
4	85	99	1.0 (ref)	1.0 (ref)	1.0 (ref)
<i>P</i> _{trend} ^f			0.61	0.94	0.88
DBP, µg/mL					
Q1: <187	90	92	1.0 (ref)	1.0 (ref)	1.0 (ref)
Q2: 187–<235	98	86	1.03 (0.67–1.58)	0.80 (0.50–1.29)	0.79 (0.49–1.28)
Q3: 235–<291	91	92	1.18 (0.78–1.78)	1.12 (0.71–1.76)	1.08 (0.68–1.71)
Q4: ≥291	90	94	1.03 (0.67–1.56)	0.90 (0.57–1.42)	0.85 (0.53–1.36)
<i>P</i> _{trend} ^d			0.71	0.61	0.58
25(OH)D:DBP molar ratio					
Q1: <9.6	87	90	1.0 (ref)	1.0 (ref)	—
Q2: 9.6–<13.0	103	89	0.86 (0.54–1.36)	0.88 (0.53–1.48)	—
Q3: 13.0–<17.2	79	95	1.00 (0.66–1.50)	1.02 (0.65–1.60)	—
Q4: ≥17.2	100	90	0.75 (0.49–1.15)	0.82 (0.51–1.32)	—
<i>P</i> _{trend} ^d			0.83	0.90	—

^aConditioned on the matching factors.

^bConditioned on the matching factors. Further adjusted for smoking status, pack-years of smoking, dairy consumption, and use of aspirin or ibuprofen.

^cConditioned on the matching factors. Further adjusted for smoking status, pack-years of smoking, dairy consumption, use of aspirin or ibuprofen, and mutually adjusted for 25(OH)D and DBP.

^dMedian of each category modeled as a continuous variable.

^eWinter quartile cutoff points (in nmol/L) = Q1: <35, Q2: 35–<49, Q3: 49–<66, Q4: ≥66; summer quartile cutoff points (in nmol/L) = Q1: <48, Q2: 48–<60, Q3: 60–<73, Q4: ≥73.

^fOrdinal variable for quartile group modeled as a continuous variable.

^gCutoff points for residual-adjusted quartiles were Q1: <54.5, Q2: 54.5–<54.8, Q3: 54.8–<55.0, Q4: ≥55.0, created by calculating residuals from the regression line of log-transformed 25(OH)D against calendar week of blood collection and adding them to the mean 25(OH)D level.

nor was DBP or the molar ratio of 25(OH)D:DBP associated with risk (Table 2). We observed no interaction between 25(OH)D and any of the following: age ($P = 0.48$), smoking ($P = 0.58$), sex ($P = 0.51$), race ($P = 0.56$), DBP ($P = 0.64$), or study center UVB exposure ($P = 0.28$). Restricting our analysis to current or former male smokers, an inverse association was suggested (Q1 vs. Q4: OR,

1.26; 95% CI, 0.67–2.36; Q2 vs. Q4: OR, 1.64; 95% CI, 0.92–2.92; Q3 vs. Q4: OR, 1.42, 95% CI, 0.80–2.53; $P_{\text{trend}} = 0.34$).

Discussion

We found no evidence of an association between vitamin D and risk of bladder cancer. Neither adjustment

for nor stratification by DBP changed the association with vitamin D. These results differ from those of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study of male smokers which found a protective association between vitamin D and bladder cancer risk (4). This difference may be explained by the inclusion of women and nonsmokers in the current analysis, as restricting the analysis to male smokers showed a modest inverse association. Although our study was sufficiently powered to detect an OR of 1.7 comparing the lowest with highest vitamin D quartile [i.e., higher risk similar in magnitude to that previously observed (ref. 4)], we did not have power to detect a weaker association, particularly in subgroups. Future studies should plan to examine differences in the association by gender and smoking status.

Importantly, the vitamin D distribution differs between the 2 cohorts; many PLCO participants were "replete" [25(OH)D, 50–75 nmol/L; 41%] and few had 25(OH)D levels < 25 nmol/L (5%). In contrast, given the population's geographic location, the majority of the ATBC Study participants had 25(OH)D levels <50 nmol/L (64%), and

many (45%) had levels <25 nmol/L. Additional studies in populations with a range of vitamin D distributions may help clarify the inconsistent findings from the 2 studies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: A.M. Mondul, S.J. Weinstein, D. Albanes

Development of methodology: R.L. Horst

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R.L. Horst, M.P. Purdue

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.M. Mondul, S.J. Weinstein, D. Albanes

Writing, review, and/or revision of the manuscript: A.M. Mondul, S.J. Weinstein, M.P. Purdue, D. Albanes

Study supervision: D. Albanes

Grant Support

This work was supported in part by intramural funding from the NIH Office of Dietary Supplements.

Received April 12, 2012; accepted May 9, 2012; published OnlineFirst May 23, 2012.

References

- Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review. *Cancer Causes Control* 2005;16:83–95.
- Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. *Am J Clin Nutr* 2004;79:362–71.
- Helzlsouer KJ. Overview of the Cohort Consortium Vitamin D Pooling Project of rarer cancers. *Am J Epidemiol* 2010;172:4–9.
- Mondul AM, Weinstein SJ, Mannisto S, Snyder K, Horst RL, Virtamo J, et al. Serum vitamin D and risk of bladder cancer. *Cancer Res* 2010;70:9218–23.
- Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial. *Control Clin Trials* 2000;21:273S–309S.
- Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of rarer cancers. *Am J Epidemiol* 2010;172:10–20.
- Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT. Serum vitamin D and risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Screening trial. *Cancer Res* 2009;69:1439–47.